Cargando…

Efficacy and safety of using aminocaproic acid and tranexamic acid during the perioperative period for treating trochanteric fractures in elderly femurs

BACKGROUND: Tranexamic acid (TXA) has long been the antifibrinolytic hemostatic drug of choice for orthopedic surgery. In recent years, the hemostatic effect of epsilon aminocaproic acid (EACA) has gradually been recognized by orthopedic surgeons and has begun to be used in hip and knee arthroplasty...

Descripción completa

Detalles Bibliográficos
Autores principales: Yusufu, Alimujiang, Haibier, Abuduwupuer, Ren, Zheng, Qin, Qi, Zhang, Ziyi, Zhou, Yuan, Ran, Jian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10316571/
https://www.ncbi.nlm.nih.gov/pubmed/37400783
http://dx.doi.org/10.1186/s12891-023-06627-z
_version_ 1785067738528481280
author Yusufu, Alimujiang
Haibier, Abuduwupuer
Ren, Zheng
Qin, Qi
Zhang, Ziyi
Zhou, Yuan
Ran, Jian
author_facet Yusufu, Alimujiang
Haibier, Abuduwupuer
Ren, Zheng
Qin, Qi
Zhang, Ziyi
Zhou, Yuan
Ran, Jian
author_sort Yusufu, Alimujiang
collection PubMed
description BACKGROUND: Tranexamic acid (TXA) has long been the antifibrinolytic hemostatic drug of choice for orthopedic surgery. In recent years, the hemostatic effect of epsilon aminocaproic acid (EACA) has gradually been recognized by orthopedic surgeons and has begun to be used in hip and knee arthroplasty with little mention of the comparison of these two drugs; Therefore, this study compared the efficacy and safety of EACA and TXA in the perioperative period of elderly patients with trochanteric fractures to verify whether EAC could be a "qualified alternative" to TXA and to provide theoretical support for the clinical application of TXA. METHODS: Two hundred and forty-three patients who received proximal femoral nail antirotation (PFNA) for trochanteric fractures from January 2021 to March 2022 at our institution were included and divided into the EACA group (n = 146) and the TXA group. (n = 97) determined by the drugs used in the perioperative period The main observations were blood loss and blood transfusion.The second second outcome was blood routine, coagulation, Hospital complications and complications after discharge. RESULTS: The perioperative EACA patients had significantly lower significant blood loss (DBL) than the TXA group (p < 0.0001) and statistically significant lower C-reactive protein in the EACA group than in the TXA group on postoperative day 1 (p = 0.022). Patients on perioperative TXA had better postoperative day one (p = 0.002) and postoperative day five erythrocyte width than the EACA group (p = 0.004). However, there was no statistically significant difference between the two groups in the remaining indicators in both drugs: blood items, coagulation indicators, blood loss, blood transfusion, length of hospital(LOH), total hospital expense, and postoperative complications (p > 0.05). CONCLUSION: The hemostatic effects and safety of EACA and TXA in the perioperative application of trochanteric fractures in the elderly are essentially similar, and EACA can be considered for use as an alternative to TXA, increasing the flexibility of physicians to use it in the clinical setting. However, the limited sample size included necessitated a high-quality, large sample of clinical studies and long-term follow-up.
format Online
Article
Text
id pubmed-10316571
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-103165712023-07-04 Efficacy and safety of using aminocaproic acid and tranexamic acid during the perioperative period for treating trochanteric fractures in elderly femurs Yusufu, Alimujiang Haibier, Abuduwupuer Ren, Zheng Qin, Qi Zhang, Ziyi Zhou, Yuan Ran, Jian BMC Musculoskelet Disord Research BACKGROUND: Tranexamic acid (TXA) has long been the antifibrinolytic hemostatic drug of choice for orthopedic surgery. In recent years, the hemostatic effect of epsilon aminocaproic acid (EACA) has gradually been recognized by orthopedic surgeons and has begun to be used in hip and knee arthroplasty with little mention of the comparison of these two drugs; Therefore, this study compared the efficacy and safety of EACA and TXA in the perioperative period of elderly patients with trochanteric fractures to verify whether EAC could be a "qualified alternative" to TXA and to provide theoretical support for the clinical application of TXA. METHODS: Two hundred and forty-three patients who received proximal femoral nail antirotation (PFNA) for trochanteric fractures from January 2021 to March 2022 at our institution were included and divided into the EACA group (n = 146) and the TXA group. (n = 97) determined by the drugs used in the perioperative period The main observations were blood loss and blood transfusion.The second second outcome was blood routine, coagulation, Hospital complications and complications after discharge. RESULTS: The perioperative EACA patients had significantly lower significant blood loss (DBL) than the TXA group (p < 0.0001) and statistically significant lower C-reactive protein in the EACA group than in the TXA group on postoperative day 1 (p = 0.022). Patients on perioperative TXA had better postoperative day one (p = 0.002) and postoperative day five erythrocyte width than the EACA group (p = 0.004). However, there was no statistically significant difference between the two groups in the remaining indicators in both drugs: blood items, coagulation indicators, blood loss, blood transfusion, length of hospital(LOH), total hospital expense, and postoperative complications (p > 0.05). CONCLUSION: The hemostatic effects and safety of EACA and TXA in the perioperative application of trochanteric fractures in the elderly are essentially similar, and EACA can be considered for use as an alternative to TXA, increasing the flexibility of physicians to use it in the clinical setting. However, the limited sample size included necessitated a high-quality, large sample of clinical studies and long-term follow-up. BioMed Central 2023-07-03 /pmc/articles/PMC10316571/ /pubmed/37400783 http://dx.doi.org/10.1186/s12891-023-06627-z Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Yusufu, Alimujiang
Haibier, Abuduwupuer
Ren, Zheng
Qin, Qi
Zhang, Ziyi
Zhou, Yuan
Ran, Jian
Efficacy and safety of using aminocaproic acid and tranexamic acid during the perioperative period for treating trochanteric fractures in elderly femurs
title Efficacy and safety of using aminocaproic acid and tranexamic acid during the perioperative period for treating trochanteric fractures in elderly femurs
title_full Efficacy and safety of using aminocaproic acid and tranexamic acid during the perioperative period for treating trochanteric fractures in elderly femurs
title_fullStr Efficacy and safety of using aminocaproic acid and tranexamic acid during the perioperative period for treating trochanteric fractures in elderly femurs
title_full_unstemmed Efficacy and safety of using aminocaproic acid and tranexamic acid during the perioperative period for treating trochanteric fractures in elderly femurs
title_short Efficacy and safety of using aminocaproic acid and tranexamic acid during the perioperative period for treating trochanteric fractures in elderly femurs
title_sort efficacy and safety of using aminocaproic acid and tranexamic acid during the perioperative period for treating trochanteric fractures in elderly femurs
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10316571/
https://www.ncbi.nlm.nih.gov/pubmed/37400783
http://dx.doi.org/10.1186/s12891-023-06627-z
work_keys_str_mv AT yusufualimujiang efficacyandsafetyofusingaminocaproicacidandtranexamicacidduringtheperioperativeperiodfortreatingtrochantericfracturesinelderlyfemurs
AT haibierabuduwupuer efficacyandsafetyofusingaminocaproicacidandtranexamicacidduringtheperioperativeperiodfortreatingtrochantericfracturesinelderlyfemurs
AT renzheng efficacyandsafetyofusingaminocaproicacidandtranexamicacidduringtheperioperativeperiodfortreatingtrochantericfracturesinelderlyfemurs
AT qinqi efficacyandsafetyofusingaminocaproicacidandtranexamicacidduringtheperioperativeperiodfortreatingtrochantericfracturesinelderlyfemurs
AT zhangziyi efficacyandsafetyofusingaminocaproicacidandtranexamicacidduringtheperioperativeperiodfortreatingtrochantericfracturesinelderlyfemurs
AT zhouyuan efficacyandsafetyofusingaminocaproicacidandtranexamicacidduringtheperioperativeperiodfortreatingtrochantericfracturesinelderlyfemurs
AT ranjian efficacyandsafetyofusingaminocaproicacidandtranexamicacidduringtheperioperativeperiodfortreatingtrochantericfracturesinelderlyfemurs